In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Künzel, Associate Director in the Functional Genomics department at AstraZeneca, about the application of arrayed ...
Using CRISPR/Cas9, scientists identified RBM5 as a vital component of leukemia cell fitness, making it a promising target for drug development. The protein HOXA9 is overexpressed in most acute myeloid ...
ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific innovation and technology transfer, ...
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to ...
CombiningTvDAO-based surrogate selection marker withthe CRISPR/Cas9 system enables the selection ofCas9-free and multigene CRISPR mutants. Disclaimer: AAAS and EurekAlert! are not responsible for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback